Skip to main content
LAB
NASDAQ Industrial Applications And Services

Standard BioTools Completes SomaLogic Divestiture, Secures $350M Upfront Cash and $550M Balance for M&A Strategy

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1.48
Mkt Cap
$542.237M
52W Low
$0.92
52W High
$1.72
52W Position info
61% above low
Off High info
14% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

LAB sits 61% above its 52-week low of $0.92.

Summary

Standard BioTools completed the sale of its SomaLogic business to Illumina, receiving $350 million upfront cash and boosting its balance sheet to approximately $550 million in cash and equivalents, enabling a new M&A-driven growth strategy.


Key Events · M&A and Partnerships · LAB

  • SomaLogic Divestiture Completed

    Standard BioTools Inc. completed the previously announced sale of its SomaLogic business to Illumina, Inc. on January 30, 2026.

  • Significant Cash Inflow

    The company received an upfront payment of $350 million in cash, with eligibility for up to $75 million in additional earnout payments and a 2% royalty on specific net revenues for 10 years.

  • Enhanced Financial Position

    Post-closing, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million, providing substantial capital for its inorganic growth strategy.

  • Strategic Repositioning

    The CEO highlighted the transaction as a 'major milestone in our strategic transformation,' positioning the company as lean, focused, and financially resourced for disciplined M&A.


Analysis · LAB · Industrial Applications And Services

Standard BioTools has finalized the sale of its SomaLogic business to Illumina, a transaction previously confirmed as 'on track' in the January 8, 2026 8-K filing. This completion brings a substantial $350 million in upfront cash, with potential for an additional $75 million in earnout payments and future royalties. The company now boasts an estimated $550 million in cash and cash equivalents, a significant liquidity boost that enables a focused inorganic growth strategy through M&A. This marks a major strategic transformation, positioning the company as 'lean, focused, and extremely well positioned' according to its CEO, and significantly de-risks its financial position while providing capital for future expansion.

At the time of this filing, LAB was trading at $1.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $542.2M. The 52-week trading range was $0.92 to $1.72. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LAB - Latest Insights

LAB
Jul 28, 2026, 8:22 AM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $0.7999
Real-time Price: $0.790 info
Change: -$0.0099 (-1%) info
Market Cap: $311.096M info
LAB
Jul 28, 2026, 8:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7937
Real-time Price: $0.790 info
Change: -$0.0037 (-0.47%) info
Market Cap: $311.096M info
LAB
Jul 28, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.82915
Real-time Price: $0.790 info
Change: -$0.03915 (-5%) info
Market Cap: $311.096M info
LAB
Jul 24, 2026, 4:38 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8332
Real-time Price: $0.790 info
Change: -$0.0432 (-5%) info
Market Cap: $311.096M info
LAB
Jul 20, 2026, 7:55 AM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $0.900
Real-time Price: $0.790 info
Change: -$0.110 (-12%) info
Market Cap: $311.096M info